{"preliminary_commentary":{"by_channel":{"x_thread":6,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["visugromab","nivolumab"],["visugromab"]],"indication":"advanced-stage, relapsed/refractory solid tumors","name":"GDFATHER","nct_id":"NCT04725474","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=gdfather-nct04725474. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"GDFATHER","arms":[{"description":"Up to 5 dose levels with visugromab (CTL-002) administered as IV monotherapy and in combination with a CPI","label":"Phase 1 (Part A; dose escalation): CTL-002 Monotherapy + Checkpoint Inhibitor Combination","type":"EXPERIMENTAL"},{"description":"At defined dose level(s) with visugromab (CTL-002)","label":"Phase 2 (Part B; expansion): visugromab (CTL-002) + Checkpoint Inhibitor Combination","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-04-30","type":"ESTIMATED"},"conditions":["Solid Tumor, Adult"],"enrollment":{"count":199,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"visugromab (CTL-002)","otherNames":[],"type":"BIOLOGICAL"},{"name":"nivolumab","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-08-19","lead_sponsor":"CatalYm GmbH","official_title":"A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The \"GDFATHER\"-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation).","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2028-04-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Adverse Events (Parts A & B)","timeFrame":"min. 2 months"},{"measure":"Determination of DLT and MTD (Part A)","timeFrame":"28 days"},{"measure":"Evaluation of clinical efficacy according RECIST V1.1 (Part B)","timeFrame":"min. 6 weeks"}],"references":[{"citation":"Melero I, de Miguel M, Cabanas EG, de Velasco G, Joerger M, Martin-Liberal J, Reig M, Konig D, Trojan J, Goebeler ME, Schuler M, Alonso G, Dummer R, Rodriguez-Ruiz ME, Yarza R, Pretelli G, Esteban-Villarubia J, Koster KL, Viltro PS, Sanduzzi-Zamparelli M, Laubli H, Koch C, Sayehli C, Gromke T, Racca F, Ramelyte E, Galle PR, Necchi A, Reck M, Trajanoski Z, Hackl H, Gogolla F, Billing J, Sattmann T, Wischhusen J, Schuberth-Wagner C, Akdemir J, Lichtenegger FS, Auckenthaler A, Fox M, Klar K, Fettes P, Liebig M, Amin A, Sachdeva S, Hermann F, Leo E. Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors. J Hematol Oncol. 2026 Jul 9. doi: 10.1186/s13045-026-01818-2. Online ahead of print.","pmid":"42426863","type":"DERIVED"}],"start_date":{"date":"2020-12-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)","url":"https://clinicaltrials.gov/study/NCT04725474"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/gdfather-nct04725474"}